Table 1.

Summary of recent stroke trials

Trial	Patients	IV tPA	TICI 2B/3	90-day mRS 0–2
				medical	endovascular
MR CLEAN	500	89%	59%	19%	33%
ESCAPE	315	75%	72%	29%	53%
EXTEND IA	70	100%	86%	40%	71%
SWIFT PRIME	196	100%	88%	36%	60%
REVASCAT	206	73%	66%	28%	44%